Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Effective dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5,792 result(s) found for: Effective dose. Displaying page 1 of 290.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2014-004346-10 Sponsor Protocol Number: N/A Start Date*: 2015-04-15
    Sponsor Name:Alder Hey Children's NHS Foundation Trust
    Full Title: Study to evaluate the optimal dose of remifentanil infusion(effective dose in 80% of patients) required to ensure apnoea (of 30 seconds duration) during magnetic resonance imaging of the heart unde...
    Medical condition: Study refers to the use of this medicine during anaesthesia given during the investigation of congenital heart disease.
    Disease:
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002795-41 Sponsor Protocol Number: B1481038 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) IT (Completed) DE (Prematurely Ended) CZ (Prematurely Ended) HU (Completed) SK (Prematurely Ended) ES (Completed) BE (Prematurely Ended) DK (Completed) SE (Completed) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003701-25 Sponsor Protocol Number: 7035-CL-0014 Start Date*: 2013-12-09
    Sponsor Name:Tacurion Pharma Inc
    Full Title: A Phase II, Multicenter,Randomization, Double-Blind, Parallel Group, Placebo-Controlled, Forced Titration Proof of Concept Study to Assess Efficacy, Safety, Tolerability and the Therapeutic Ratio ...
    Medical condition: Nocturia associated with nocturnal polyuria
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004857 10064016 Nocturnal polyuria LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PL (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000630-17 Sponsor Protocol Number: MER-XMT-1536-1 Start Date*: 2021-09-21
    Sponsor Name:Mersana Therapeutics, Inc.
    Full Title: A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
    Medical condition: High grade serous ovarian cancer or non-small cell lung cancer (NSCLC), adenocarcinoma subtype
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) NO (Completed) LT (Completed) CZ (Completed) HU (Completed) BG (Completed) FI (Completed) PL (Completed) DK (Completed) IT (Completed) AT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000920-25 Sponsor Protocol Number: STH19177 Start Date*: 2016-04-15
    Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust
    Full Title: A study of very low dose twice-daily compared to standard low dose once-daily aspirin following acute coronary syndromes - WILL lOWer dose aspirin be more effective following ACS?
    Medical condition: Acute coronary syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-018187-10 Sponsor Protocol Number: DODO1011 Start Date*: 2010-04-21
    Sponsor Name:Ziekenhuisgroep Twente
    Full Title: Double dose treatment: Corticosteroid injection therapy in arthritis
    Medical condition: To determine whether doubling the dose of triamcinolone injections in the treatment of arthritis in knee joints is more effective, both in number of responding patients and in duration of response ...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001117-86 Sponsor Protocol Number: 16/0340 Start Date*: 2017-07-25
    Sponsor Name:University College London
    Full Title: A phase IV, prospective, randomised single-blind UK multicentre non-inferiority trial of low-dose versus standard dose rituximab for prevention of relapses in acquired TTP
    Medical condition: Acquired thrombotic thrombocytopenic purpura
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2018-002830-19 Sponsor Protocol Number: RC31-18-0269 Start Date*: 2018-11-16
    Sponsor Name: Toulouse University Hospital
    Full Title: A randomized, double blind placebo-controlled multicenter study of the efficacy and safety of dupilumab in patients with moderate to severe hand eczema refractory to highly potent topical corticost...
    Medical condition: Chronic hand eczema
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000323-33 Sponsor Protocol Number: BAY86-6150,IMPACT15534 Start Date*: 2012-09-25
    Sponsor Name:Bayer HealthCare AG
    Full Title: A Phase 2/3, multicenter, open-label clinical study to assess the safety and efficacy of BAY86-6150 in subjects with hemophilia A or B with inhibitors, composed of 2 Parts (A & B). Part A: Sequenti...
    Medical condition: Subjects with hemophilia A or B with inhibitors
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004850 10053751 Hemophilia A with anti factor VIII LLT
    14.1 100000004850 10053752 Hemophilia B with anti factor IX LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) DK (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-005915-39 Sponsor Protocol Number: RT-CoV-2_01 Start Date*: 2021-02-19
    Sponsor Name:REITHERA SRL
    Full Title: COVID-19 A Phase II/III, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of GRAd-COV2 Vaccine in Adults Aged 18 Years and Older
    Medical condition: Subjects exposed to SARS-COV-2 risk of infectious
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-002646-36 Sponsor Protocol Number: B1481022 Start Date*: 2014-02-14
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, ny 10017
    Full Title: PHASE 3 MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP EVALUATION OF THE EFFICACY, SAFETY, AND TOLERABILITY OF BOCOCIZUMAB (PF-04950615), IN REDUCING THE OCCURRENCE OF M...
    Medical condition: atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004866 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) NL (Prematurely Ended) FI (Prematurely Ended) DE (Prematurely Ended) HU (Completed) CZ (Prematurely Ended) SE (Completed) SK (Prematurely Ended) ES (Completed) IT (Completed) BE (Prematurely Ended) DK (Completed) PL (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000722-30 Sponsor Protocol Number: B0151005 Start Date*: 2012-04-12
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A MULTICENTER OPEN-LABEL EXTENSION STUDY FOR SUBJECTS WHO PARTICIPATED IN STUDY B0151003 (ANDANTE II)
    Medical condition: Crohn’s disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10011401 Crohn's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) GR (Prematurely Ended) BE (Completed) DK (Completed) HU (Completed) IT (Completed) CZ (Completed) AT (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2017-003598-33 Sponsor Protocol Number: LJ401-HH01 Start Date*: 2018-04-03
    Sponsor Name:La Jolla Pharmaceutical Company
    Full Title: A Phase 2, Multi-center, Randomized, Placebo-controlled, Single-blind Study with LJPC-401 for the Treatment of Iron Overload in Adult Patients with Hereditary Hemochromatosis
    Medical condition: Hereditary Hemochromatosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-001841-24 Sponsor Protocol Number: C25608/4027/BP/EU Start Date*: 2008-08-04
    Sponsor Name:Cephalon France
    Full Title: A European Multicenter Open-label Study of Breakthrough Cancer Pain: Assessment of Fentanyl Buccal Tablets Titration and Treatment in Opioid-Tolerant Patients
    Medical condition: Breakthrough Pain (BTP) in cancer patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10064556 Breakthrough pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) NL (Completed) FR (Completed) IE (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-013462-25 Sponsor Protocol Number: MW001 Start Date*: 2009-09-28
    Sponsor Name:NHS Greater Glasgow and Clyde Health Board
    Full Title: A dose finding study for ultrasound guided anterior psoas compartment blocks in patients with a fractured neck of femur
    Medical condition: Proximal traumatic fractured neck of femur
    Disease: Version SOC Term Classification Code Term Level
    10029173 Nerve block LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-005028-11 Sponsor Protocol Number: I4V-MC-JAIM Start Date*: 2019-10-24
    Sponsor Name:Eli Lilly and Company
    Full Title: A Phase 3, Double-Blind, Multicenter Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Patients with Systemic Lupus Erythematosus (SLE)
    Medical condition: Systemic Lupus Erythematosus (SLE)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004859 10025139 Lupus erythematosus systemic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) HU (Completed) PL (Completed) BE (Completed) ES (Prematurely Ended) GR (Completed) NL (Completed) HR (Completed) IT (Prematurely Ended) RO (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004664-36 Sponsor Protocol Number: EVE116-CT03-2017 Start Date*: 2018-06-19
    Sponsor Name:Evestra GmbH
    Full Title: Characterization of ovulation inhibition of a new vaginal delivery system containing trimegestone - an open-label, single-centre study in healthy females of childbearing potential
    Medical condition: Investigation of ovulation inhibition for indication of contraception
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-001862-13 Sponsor Protocol Number: AB19001 Start Date*: 2020-03-12
    Sponsor Name:ABScience
    Full Title: A prospective, multicenter, randomised, double-blind, placebo-controlled, parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with Riluzole versus placebo ...
    Medical condition: patients suffering from Amyotrophic Lateral Sclerosis (ALS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10002026 Amyotrophic lateral sclerosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed) FR (Trial now transitioned) BE (Prematurely Ended) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) PT (Ongoing) ES (Restarted) DK (Trial now transitioned) PL (Ongoing) IE (Prematurely Ended) IT (Prematurely Ended) NO (Trial now transitioned) GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2007-005225-30 Sponsor Protocol Number: GWCA0701 Start Date*: 2008-01-17
    Sponsor Name:GW Pharma Ltd.
    Full Title: A double blind, randomized, placebo controlled, parallel group dose range exploration study of Sativex® in relieving pain in patients with advanced cancer, who experience inadequate analgesia durin...
    Medical condition: Pain in patients with advanced cancer, who experience inadequate analgesia during optimized chronic opioid therapy.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) IT (Completed) ES (Completed) FI (Completed) GB (Completed) BE (Completed) DE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-001151-40 Sponsor Protocol Number: CTU148N Start Date*: 2019-07-09
    Sponsor Name:RIEMSER Pharma GmbH
    Full Title: Phase II pilot study: To determine an effective and tolerable dose of Hylase® "Dessau" (bovine hyaluronidase) in the treatment of hyaluronic acid filler overshoots by injection into defined areas o...
    Medical condition: In this study, healthy subjects get an artificial over-injection with Hyaluron acid filler on the back of the hands. To demonstrate the effectiveness of hylase® "Dessau" as an antidote for hyaluro...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 02:26:36 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA